Neurology · 2018 · 29 citations · 5 references
Life SciencesNeurologyNeuroscienceNeurodegenerationNeuropathologySleep MedicineAutoimmune Neurological DisordersNeurodegenerative DiseasesNeurodegenerative DisordersProtein Aggregation DisordersSleep-wake DisordersTau PathologyAntibodiesCerebrospinal Fluid TauTau HyperphosphorylationTau-associated Neurodegeneration
In 2014, a novel tauopathy characterized by REM sleep behavior disorder (RBD), sleep apnea, and stridor was first reported.1 Association with serum and CSF antibodies against IgLON5, a neuronal cell adhesion molecule of unknown function, was found in all patients.1 Neuropathologic examinations revealed neuronal accumulation of hyperphosphorylated 3-repeat (3R) and 4-repeat (4R) tau deposits in the hypothalamus and tegmental brainstem nuclei as the most relevant finding in the absence of inflammatory changes.2
5
Lídia Sabater, Carles Gaig, Ellen Gelpí et al. · The Lancet Neurology · 2014 · 551 citations · Full text
Medicine, Neurology, Psychiatry +14
Clinical manifestations of the anti-IgLON5 disease
Carles Gaig, Francesc Graus, Birgit Högl et al. · Neurology · 2017 · 414 citations · Full text
Medicine, Immunology, Neurology +17
Neuropathological criteria of anti-IgLON5-related tauopathy
Ellen Gelpí, Romana Höftberger, Francesc Graus et al. · Acta Neuropathologica · 2016 · 239 citations · Full text
Isolated dysphagia as initial sign of anti-IgLON5 syndrome
J. Schröder, Nico Melzer, Tobias Ruck et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 50 citations · Full text
Medicine, Neurology, Otolaryngology +14